Photo: streetinsider.com
Novo Nordisk's CagriSema Cuts Blood Pressure in Obesity Patients by 10.9 mmHg
Novo Nordisks CagriSema treatment reduced systolic blood pressure by 10.9 mmHg in obesity patients, showcasing significant potential for combating hypertension and cardiovascular disease.
- In the phase 3 REDEFINE 1 trial, Novo Nordisk reported a 10.9 mmHg reduction in systolic blood pressure among obesity patients treated with CagriSema over 68 weeks.
- The trial revealed that 40% of participants on medication for hypertension could either reduce or stop their medication during the study period.
- CagriSema is a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, designed to aid in weight loss and lower inflammation in obesity patients.
Why It Matters
The findings underscore the potential of CagriSema not only for weight loss but also for addressing hypertension, which is crucial in reducing the risk of cardiovascular disease. This could reshape treatment paradigms for obesity-related health issues.